Skin disease related to metabolic syndrome in women

Misitzis, Angelica; Cunha, Paulo Rowilson; Kroumpouzos, George

doi:10.1016/j.ijwd.2019.06.030

Cited by 13 publications

(25 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Given that psoriasis is a chronic inflammatory disease, it poses a greater risk of CVD in women. 9 This study 5 showed higher prevalence of metabolic syndrome in cases with psoriasis than in controls, which is in accordance with the research conducted by Regitz-Zagrosek et al 8,9 It has been concluded in a study done by Pietrzak et al 10 that the relation of CVD and psoriasis in females intensifies with age. However, no such associations have been recorded in this study.…”

supporting

confidence: 89%

Cardiovascular Comorbidities in Women with Psoriasis

Annabathula¹

2020

Indian Journal of Cardiovascular Disease in Women WINCARS

View full text Add to dashboard Cite

supporting

confidence: 89%

Cardiovascular Comorbidities in Women with Psoriasis

Annabathula¹

2020

Indian Journal of Cardiovascular Disease in Women WINCARS

View full text Add to dashboard Cite

“…High testosterone, low sex hormone-binding globulin (SHBG), and low estrogen levels increase the risks of MetSyn and T2DM in women. In this study, several diseases mediated by sex hormones, including PCOS, acanthosis nigricans, acne vulgaris, and pattern alopecia, were associated with IR and increased risk for MetSyn [55]. Furthermore, Weeker et al…”

Section: Indicators Related To Associated Diseases/syndromessupporting

confidence: 51%

“…Androgens (Testosterone) and SHBG: Men with low concentrations of total testosterone (TT), SHBG, or free testosterone (FT) were more likely to have prevalent MetSyn (ORs per quartile decrease were 1.69 (95%CI: 1.60e1.77), 1.73 (95%CI: 1.62e1.85), and 1.46 (95%CI: 1.36e1.57) for TT, SHBG, and FT, respectively) and incident MetSyn [85]. This association was also observed in women (not in a meta-analysis) [55]. In perimenopausal and postmenopausal women, androgenic markers (testosterone and SHBG) are more important than estrogens in the assessment of MetSyn.…”

Section: Indicators Related To Blood Biomarkersmentioning

confidence: 87%

Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status

Gesteiro

Megía

Guadalupe‐Grau

et al. 2021

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Aims: a) To analyze the relationship of known and emerging biomarkers/indicators for early risk identification of cardiometabolic health risk; b) to identify early risk markers to be used in both clinical and nonclinical settings; and c) to propose a definition of early risk identification in terms of pre-metabolic syndrome (PreMetSyn). Data synthesis: Pubmed/Medline, Web of Science, Embase, and Cochrane were searched for Systematic Reviews and Meta-analysis. Selected studies were evaluated, and relevant data were extracted and synthesized. Conclusions: Serum uric acid is a good predictive biomarker of metabolic syndrome (MetSyn) and has been associated with non-alcoholic liver fat disease (NAFLD) and type 2 diabetes. NAFLD emerges as an early risk indicator of PreMetSyn by itself. Muscle strength should also be included as an early risk marker of cardiometabolic health. High serum triglycerides and waist circumference confirm their predictive value regarding MetSyn. Indicators related to an inflammatory/proinflammatory status usually linked to MetSyn showed limited evidence as robust biomarkers for PreMetSyn. Authors suggest defining PreMetSyn related to cardiometabolic risk. It is also necessary to determine how close people are to the cut-off point of MetSyn components, including emerging indicators proposed by our review. Some biomarkers could be used as indicators of PreMetSyn, before any of the MetSyn components appear, allowing early health interventions to prevent its development. Defining a PreMetSyn status might consider both emerging indicators and those variables already included in the definition of MetSyn. New indicators should be considered to create a new risk score specifically meant for PreMetSyn.

show abstract

“…Finally, acanthosis nigricans and skin tags were much more prevalent in Keen et al’s report, at 30% and 9%, respectively [ 10 ], than in our sample. This difference may be attributed to differences in our samples’ fasting blood glucose and fasting insulin levels, which serve as reflections of insulin resistance, the pathophysiology responsible for acanthosis nigricans and skin tags [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center

Aljefri¹,

Alahmadi²,

Alajmi³

et al. 2021

Cureus

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder affecting 5%-10% of women worldwide. PCOS patients usually present with cutaneous manifestations of hyperandrogenism, such as acne, hirsutism, and androgenic alopecia.Objective: To estimate the prevalence of dermatological manifestations and their association with hormonal changes in PCOS patients. In addition, this study aimed to estimate the prevalence of comorbidities associated with PCOS and to demonstrate the referral pattern among Dermatology, Gynecology, and Primary Health Care (PHC).Methods: This is a cross-sectional study conducted at King Abdulaziz Medical City (KAMC) in Jeddah, Saudi Arabia. All PCOS patients who attended KAMC from 2016 to 2021 were included. Data were collected through a retrospective chart review of the electronic medical record system (BestCare) and by utilizing a structured data collection sheet.Results: A total of 447 female patients were diagnosed with PCOS with a median age of 29 years and a median BMI of 28.76 kg/m 2 .The prevalence of cutaneous manifestations among patients was 68%. Hirsutism (47.3%), acne vulgaris (40.6%), and androgenic alopecia (20.3%) were the most common manifestations. The most common hormonal abnormalities were raised luteinizing hormone (LH) levels in 220 (49.1%) patients and raised LH/follicle-stimulating hormone (FSH) ratio in 159 (35.5%) patients. FSH, LH/FSH ratio, and age were significant predictors for acne vulgaris (P-value=0.01, 0.04, and 0.01, respectively). Obesity (44.20%), infertility (25.70%), and dyslipidemia (17%) were the most common comorbidities in our sample. Most patients' first visits and follow-ups were in PHC. Conclusion:The prevalence of cutaneous manifestations among PCOS patients is relatively high and plays a significant role in making the diagnosis. Therefore, physicians across multiple specialties need to be more aware of the full spectrum of PCOS presentations to alleviate it from its under-diagnosed status.

show abstract

Skin disease related to metabolic syndrome in women

Cited by 13 publications

References 160 publications

Cardiovascular Comorbidities in Women with Psoriasis

Cardiovascular Comorbidities in Women with Psoriasis

Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status

Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center

Contact Info

Product

Resources

About